Cargando…

Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14

DLBCL is an aggressive lymphoma treated with R-CHOP. Recently, attempts have been made to improve the outcome by increasing both dose-density and intensity but there have been no benefits in terms of survival. When treating malignancies RDI is important to consider but there is little published info...

Descripción completa

Detalles Bibliográficos
Autores principales: Gutiérrez, Antonio, Bento, Leyre, Bautista-Gili, Antonia Maria, Garcia, Francesc, Martinez-Serra, Jordi, Sanchez, Blanca, Martorell, Clara, Gines, Jordi, Garcia, Lucia, Gimeno, Eva, Ferraro, Mariana, Del Campo, Raquel, Bargay, Joan, Perez, Albert, Vercher, Javier, Scaff, Miguel, Pacheco, Ana, Ballester, Carmen, Garcia, Florencia, Ramos, Rafael, Salar, Antonio, Besalduch, Joan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4409365/
https://www.ncbi.nlm.nih.gov/pubmed/25909361
http://dx.doi.org/10.1371/journal.pone.0123978
_version_ 1782368190814224384
author Gutiérrez, Antonio
Bento, Leyre
Bautista-Gili, Antonia Maria
Garcia, Francesc
Martinez-Serra, Jordi
Sanchez, Blanca
Martorell, Clara
Gines, Jordi
Garcia, Lucia
Gimeno, Eva
Ferraro, Mariana
Del Campo, Raquel
Bargay, Joan
Perez, Albert
Vercher, Javier
Scaff, Miguel
Pacheco, Ana
Ballester, Carmen
Garcia, Florencia
Ramos, Rafael
Salar, Antonio
Besalduch, Joan
author_facet Gutiérrez, Antonio
Bento, Leyre
Bautista-Gili, Antonia Maria
Garcia, Francesc
Martinez-Serra, Jordi
Sanchez, Blanca
Martorell, Clara
Gines, Jordi
Garcia, Lucia
Gimeno, Eva
Ferraro, Mariana
Del Campo, Raquel
Bargay, Joan
Perez, Albert
Vercher, Javier
Scaff, Miguel
Pacheco, Ana
Ballester, Carmen
Garcia, Florencia
Ramos, Rafael
Salar, Antonio
Besalduch, Joan
author_sort Gutiérrez, Antonio
collection PubMed
description DLBCL is an aggressive lymphoma treated with R-CHOP. Recently, attempts have been made to improve the outcome by increasing both dose-density and intensity but there have been no benefits in terms of survival. When treating malignancies RDI is important to consider but there is little published information on DLBCL. The purpose of this study was to analyze the differential prognostic impact of RDI in two cohorts of DLBCL patients treated with R-CHOP21 or R-CHOP14. From January 2001 to August 2013 we included DLBCL patients homogenously treated with R-CHOP21 or R-CHOP14, with or without radiotherapy, at University Hospital Son Espases, Hospital Son Llatzer of Palma and Hospital del Mar of Barcelona (N = 157). In order to avoid selection bias the patients were retrospectively identified from the Pathology Department and Pharmacy registries. Median follow-up was 68 months. There was no difference in the response or survival between the two cohorts. In the R-CHOP21 group, both a reduction higher than 15% in RDI (RR 7.41) and R-IPI (RR 2.99) were independently associated with OS. However, a reduction higher than 15% in RDI (RR 4.41) was only noted for PFS. In the R-CHOP14 group, NCCN-IPI (RR 7.09) and B-symptoms (RR 5.37) for OS; AA stage III-IV (RR 6.26) and bulky disease (RR 4.05) for PFS. There was a trend towards a higher rate of RDI reduction observed in the R-CHOP14 group but it only made an impact in the R-CHOP21 group. We conclude that R-CHOP21 and R-CHOP14 are equivalent regimens in terms of response and survival, but only if RDI reductions are avoided. For patients receiving R-CHOP21 we recommend using clinical and support measures in order to avoid RDI reductions.
format Online
Article
Text
id pubmed-4409365
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-44093652015-05-12 Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14 Gutiérrez, Antonio Bento, Leyre Bautista-Gili, Antonia Maria Garcia, Francesc Martinez-Serra, Jordi Sanchez, Blanca Martorell, Clara Gines, Jordi Garcia, Lucia Gimeno, Eva Ferraro, Mariana Del Campo, Raquel Bargay, Joan Perez, Albert Vercher, Javier Scaff, Miguel Pacheco, Ana Ballester, Carmen Garcia, Florencia Ramos, Rafael Salar, Antonio Besalduch, Joan PLoS One Research Article DLBCL is an aggressive lymphoma treated with R-CHOP. Recently, attempts have been made to improve the outcome by increasing both dose-density and intensity but there have been no benefits in terms of survival. When treating malignancies RDI is important to consider but there is little published information on DLBCL. The purpose of this study was to analyze the differential prognostic impact of RDI in two cohorts of DLBCL patients treated with R-CHOP21 or R-CHOP14. From January 2001 to August 2013 we included DLBCL patients homogenously treated with R-CHOP21 or R-CHOP14, with or without radiotherapy, at University Hospital Son Espases, Hospital Son Llatzer of Palma and Hospital del Mar of Barcelona (N = 157). In order to avoid selection bias the patients were retrospectively identified from the Pathology Department and Pharmacy registries. Median follow-up was 68 months. There was no difference in the response or survival between the two cohorts. In the R-CHOP21 group, both a reduction higher than 15% in RDI (RR 7.41) and R-IPI (RR 2.99) were independently associated with OS. However, a reduction higher than 15% in RDI (RR 4.41) was only noted for PFS. In the R-CHOP14 group, NCCN-IPI (RR 7.09) and B-symptoms (RR 5.37) for OS; AA stage III-IV (RR 6.26) and bulky disease (RR 4.05) for PFS. There was a trend towards a higher rate of RDI reduction observed in the R-CHOP14 group but it only made an impact in the R-CHOP21 group. We conclude that R-CHOP21 and R-CHOP14 are equivalent regimens in terms of response and survival, but only if RDI reductions are avoided. For patients receiving R-CHOP21 we recommend using clinical and support measures in order to avoid RDI reductions. Public Library of Science 2015-04-24 /pmc/articles/PMC4409365/ /pubmed/25909361 http://dx.doi.org/10.1371/journal.pone.0123978 Text en © 2015 Gutiérrez et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Gutiérrez, Antonio
Bento, Leyre
Bautista-Gili, Antonia Maria
Garcia, Francesc
Martinez-Serra, Jordi
Sanchez, Blanca
Martorell, Clara
Gines, Jordi
Garcia, Lucia
Gimeno, Eva
Ferraro, Mariana
Del Campo, Raquel
Bargay, Joan
Perez, Albert
Vercher, Javier
Scaff, Miguel
Pacheco, Ana
Ballester, Carmen
Garcia, Florencia
Ramos, Rafael
Salar, Antonio
Besalduch, Joan
Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14
title Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14
title_full Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14
title_fullStr Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14
title_full_unstemmed Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14
title_short Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14
title_sort differential impact of relative dose-intensity reductions in diffuse large b-cell lymphoma treated with r-chop21 or r-chop14
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4409365/
https://www.ncbi.nlm.nih.gov/pubmed/25909361
http://dx.doi.org/10.1371/journal.pone.0123978
work_keys_str_mv AT gutierrezantonio differentialimpactofrelativedoseintensityreductionsindiffuselargebcelllymphomatreatedwithrchop21orrchop14
AT bentoleyre differentialimpactofrelativedoseintensityreductionsindiffuselargebcelllymphomatreatedwithrchop21orrchop14
AT bautistagiliantoniamaria differentialimpactofrelativedoseintensityreductionsindiffuselargebcelllymphomatreatedwithrchop21orrchop14
AT garciafrancesc differentialimpactofrelativedoseintensityreductionsindiffuselargebcelllymphomatreatedwithrchop21orrchop14
AT martinezserrajordi differentialimpactofrelativedoseintensityreductionsindiffuselargebcelllymphomatreatedwithrchop21orrchop14
AT sanchezblanca differentialimpactofrelativedoseintensityreductionsindiffuselargebcelllymphomatreatedwithrchop21orrchop14
AT martorellclara differentialimpactofrelativedoseintensityreductionsindiffuselargebcelllymphomatreatedwithrchop21orrchop14
AT ginesjordi differentialimpactofrelativedoseintensityreductionsindiffuselargebcelllymphomatreatedwithrchop21orrchop14
AT garcialucia differentialimpactofrelativedoseintensityreductionsindiffuselargebcelllymphomatreatedwithrchop21orrchop14
AT gimenoeva differentialimpactofrelativedoseintensityreductionsindiffuselargebcelllymphomatreatedwithrchop21orrchop14
AT ferraromariana differentialimpactofrelativedoseintensityreductionsindiffuselargebcelllymphomatreatedwithrchop21orrchop14
AT delcamporaquel differentialimpactofrelativedoseintensityreductionsindiffuselargebcelllymphomatreatedwithrchop21orrchop14
AT bargayjoan differentialimpactofrelativedoseintensityreductionsindiffuselargebcelllymphomatreatedwithrchop21orrchop14
AT perezalbert differentialimpactofrelativedoseintensityreductionsindiffuselargebcelllymphomatreatedwithrchop21orrchop14
AT vercherjavier differentialimpactofrelativedoseintensityreductionsindiffuselargebcelllymphomatreatedwithrchop21orrchop14
AT scaffmiguel differentialimpactofrelativedoseintensityreductionsindiffuselargebcelllymphomatreatedwithrchop21orrchop14
AT pachecoana differentialimpactofrelativedoseintensityreductionsindiffuselargebcelllymphomatreatedwithrchop21orrchop14
AT ballestercarmen differentialimpactofrelativedoseintensityreductionsindiffuselargebcelllymphomatreatedwithrchop21orrchop14
AT garciaflorencia differentialimpactofrelativedoseintensityreductionsindiffuselargebcelllymphomatreatedwithrchop21orrchop14
AT ramosrafael differentialimpactofrelativedoseintensityreductionsindiffuselargebcelllymphomatreatedwithrchop21orrchop14
AT salarantonio differentialimpactofrelativedoseintensityreductionsindiffuselargebcelllymphomatreatedwithrchop21orrchop14
AT besalduchjoan differentialimpactofrelativedoseintensityreductionsindiffuselargebcelllymphomatreatedwithrchop21orrchop14